Tempus AI's Personalis deal gains investor attention after Moderna cancer vaccine results
Shares of both companies surged following Moderna's cancer therapy announcement, but observers say the $1.5B acquisition terms are unlikely to change.
What to know
- Tempus AI's previously quiet $1.5 billion acquisition of Personalis suddenly attracted investor interest after Moderna announced positive cancer vaccine results built on Personalis's genomic sequencing technology.
- Both stocks surged on speculation the deal terms could be renegotiated, but observers say Personalis and its 13% shareholder Merck lack leverage to change the agreement.
- The deal highlights how Personalis's technology has become critical infrastructure in a major pharma breakthrough, raising questions about whether the original valuation reflected that strategic importance.
Tempus AI appears undervalued relative to the strategic importance of Personalis technology to Moderna and Merck's cancer work.
-
“Tempus only ~20%, this made me bought this position yesterday.”
Itsallaboutmargin · Reddit
“For context: Tempus AI has a pending deal to Personalis, which is the gene sequencing technology behind Moderna's cancer vaccine work. Yesterday Moderna's jumped ~200% whereas Tempus only ~20%, this made me bought this position yesterday.”
Itsallaboutmargin, Reddit user · Reddit
Tempus AI Acquiring companyPersonalis Genomic sequencing company being acquiredModerna Pharmaceutical companyMerck 13% shareholder in Personalis
The record 3 articles and posts · last 30 days
What people are saying 2 voices from 1 site · verbatim
- Aug 20
-
Shares of both Tempus and Personalis were up sharply yesterday (Personalis is up 22% since Tuesday), as investors bet the deal will be renegotiated. But observers and investors tell me that there’s little that Personalis — or Merck, which owns 13% of the company — can do to change the terms. Read more from Rohan Goswami:
-
A tiny biotech deal announced in July is suddenly attracting a lot of attention: Tempus AI agreed to acquire Personalis, a Merck-backed company which provides advanced genomic sequencing and analytics for cancer treatments, for $1.5 billion.